The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype
Open accessAbstract
Particulate vaccines are emerging promising technologies for the creation of tunable prophylactics against a wide variety of conditions. Vesicular and solid biodegradable polymer platforms, exemplified by liposomes and polyesters, respectively, are two of the most ubiquitous platforms in vaccine delivery studies. Here we directly compared the efficacy of each in a long-term immunization study and in protection against a model bacterial antigen. Immunization with poly(lactide-co-glycolide) (PLGA) nanoparticles elicited prolonged antibody titers compared to liposomes and alum. The magnitude of the cellular immune response was also highest in mice vaccinated with PLGA, which also showed a higher frequency of effector-like memory T cell phenotype, leading to an effective clearance of intracellular bacteria. The difference in performance of these two common particulate platforms is shown not to be due to material differences but appears to be connected to the kinetics of antigen delivery. Thus, this study highlights the importance of sustained antigen release mediated by particulate platforms and its role in the long-term appearance of effector memory cellular response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846
Preferential Localization of Effector Memory Cells in Nonlymphoid Tissue
Masopust, D., Vezys, V., Marzo, A. L., & Lefrançois, L. (2001) · Science · doi:10.1126/science.1058867 · Cited by 1,952 · cited 1×
“Lastly, PLGA generates memory CD8þ T cells that elicit immediate effector functions in response to pathogen entry and rapid secondary expansion to rapidly clear the infection [42,43].”
BackgroundJoshi, N. S., Cui, W., Chandele, A., Lee, H. K., Urso, D. R., Hagman, J., Gapin, L., & Kaech, S. M. (2007) · Immunity · doi:10.1016/j.immuni.2007.07.010 · Cited by 1,861
Self-citationExploiting lymphatic transport and complement activation in nanoparticle vaccines
Reddy, S. T., van der Vlies, A. J., Simeoni, E., Angeli, V., Randolph, G. J., O'Neil, C. P., Lee, L. K., Swartz, M. A., & Hubbell, J. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1332 · Cited by 1,350
Immunological mechanisms of vaccination
Pulendran, B., & Ahmed, R. (2011) · Nature Immunology · doi:10.1038/ni.2039 · Cited by 1,089
Towards an understanding of the adjuvant action of aluminium
Marrack, P., McKee, A. S., & Munks, M. W. (2009) · Nature Reviews Immunology · doi:10.1038/nri2510 · Cited by 887
Liposomes as immunological adjuvants
ALLISON, A. C., & GREGORIADIS, G. (1974) · Nature · doi:10.1038/252252a0 · Cited by 675
From Vaccines to Memory and Back
Sallusto, F., Lanzavecchia, A., Araki, K., & Ahmed, R. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.008 · Cited by 637
Kaech, S. M., & Wherry, E. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.08.007 · Cited by 625
Self-citationTranslating Innate Immunity into Immunological Memory: Implications for Vaccine Development
Pulendran, B., & Ahmed, R. (2006) · Cell · doi:10.1016/j.cell.2006.02.019 · Cited by 625
Kalia, V., Sarkar, S., Subramaniam, S., Haining, W. N., Smith, K. A., & Ahmed, R. (2010) · Immunity · doi:10.1016/j.immuni.2009.11.010 · Cited by 587
Moon, J. J., Suh, H., Bershteyn, A., Stephan, M. T., Liu, H., Huang, B., Sohail, M., Luo, S., Ho Um, S., Khant, H., et al. (2011) · Nature Materials · doi:10.1038/nmat2960 · Cited by 564
Nanotechnology in vaccine delivery
Peek, L. J., Middaugh, C. R., & Berkland, C. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.017 · Cited by 562
Recent advances in the discovery and delivery of vaccine adjuvants
O'Hagan, D. T., & Valiante, N. M. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1176 · Cited by 434
Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination
Badovinac, V. P., Messingham, K. A. N., Jabbari, A., Haring, J. S., & Harty, J. T. (2005) · Nature Medicine · doi:10.1038/nm1257 · Cited by 402
Stimulation History Dictates Memory CD8 T Cell Phenotype: Implications for Prime-Boost Vaccination
Masopust, D., Ha, S.-J., Vezys, V., & Ahmed, R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.831 · Cited by 315
Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy
Demento, S. L., Eisenbarth, S. C., Foellmer, H. G., Platt, C., Caplan, M. J., Mark Saltzman, W., Mellman, I., Ledizet, M., Fikrig, E., Flavell, R. A., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.034 · Cited by 290
Self-citationGeneration of effector CD8+ T cells and their conversion to memory T cells
Cui, W., & Kaech, S. M. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00926.x · Cited by 286
Self-citationBiodegradable microparticles as controlled release antigen delivery systems.
O’Hagan, D. T., Rahman, D., McGee, J. P., Jeffery, H., Davies, M. C., Williams, P. M., Davis, S. S., & Challacombe, S. (1991) · PubMed Central · Cited by 270
Mohanan, D., Slütter, B., Henriksen-Lacey, M., Jiskoot, W., Bouwstra, J. A., Perrie, Y., Kündig, T. M., Gander, B., & Johansen, P. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.012 · Cited by 229
Zhang, Z., Tongchusak, S., Mizukami, Y., Kang, Y. J., Ioji, T., Touma, M., Reinhold, B., Keskin, D. B., Reinherz, E. L., & Sasada, T. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.067 · Cited by 228
PEGylation as a tool for the biomedical engineering of surface modified microparticles
Wattendorf, U., & Merkle, H. P. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21350 · Cited by 227
Nanoparticle Delivery Systems in Cancer Vaccines
Krishnamachari, Y., Geary, S. M., Lemke, C. D., & Salem, A. K. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0241-4 · Cited by 219
Nanotechnology solutions for mucosal immunization
Chadwick, S., Kriegel, C., & Amiji, M. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.012 · Cited by 203
Cruz, L. J., Tacken, P. J., Fokkink, R., & Figdor, C. G. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.082 · Cited by 201
Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines
Demento, S. L., Siefert, A. L., Bandyopadhyay, A., Sharp, F. A., & Fahmy, T. M. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2011.02.004 · Cited by 176
Self-citationLook, M., Bandyopadhyay, A., Blum, J. S., & Fahmy, T. M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.011 · Cited by 163
Self-citationHarding, C. V., Collins, D. S., Kanagawa, O., & Unanue, E. R. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.9.2860 · Cited by 161
Krishnan, L., Dicaire, C. J., Patel, G. B., & Sprott, G. D. (2000) · Infection and Immunity · doi:10.1128/iai.68.1.54-63.2000 · Cited by 158
The impact of nanoparticle ligand density on dendritic-cell targeted vaccines
Bandyopadhyay, A., Fine, R. L., Demento, S., Bockenstedt, L. K., & Fahmy, T. M. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.12.054 · Cited by 141
Self-citationPetersen, L. K., Ramer‐Tait, A. E., Broderick, S., Kong, C.-S., Ulery, B. D., Rajan, K., Wannemuehler, M. J., & Narasimhan, B. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.05.063 · Cited by 138
Demento, S. L., Bonafé, N., Cui, W., Kaech, S. M., Caplan, M. J., Fikrig, E., Ledizet, M., & Fahmy, T. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000768 · Cited by 134
Self-citationPotential of Nanoparticulate Drug Delivery Systems by Intranasal Administration
Ali, J., Ali, M., Baboota, S., Sahni, J. K., Ramassamy, C., Dao, L. H., & Bhavna (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791164108 · Cited by 130
Cui, W., Joshi, N. S., Jiang, A., & Kaech, S. M. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.088 · Cited by 121
Self-citationVaccines and the Future of Human Immunology
Germain, R. N. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.014 · Cited by 110
Dudani, R., Chapdelaine, Y., van Faassen, H., Smith, D. K., Shen, H., Krishnan, L., & Sad, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5737 · Cited by 98
Nanoparticles as Protein and Gene Carriers to Mucosal Surfaces
de la Fuente, M., Csaba, N., García-Fuentes, M., & Alonso, M. J. (2008) · Nanomedicine · doi:10.2217/17435889.3.6.845 · Cited by 93
Design Opportunities for Actively Targeted Nanoparticle Vaccines
Fahmy, T. M., Demento, S. L., Caplan, M. J., Mellman, I., & Saltzman, W. M. (2008) · Nanomedicine · doi:10.2217/17435889.3.3.343 · Cited by 87
Self-citationFaisal, S. M., Yan, W., McDonough, S. P., & Chang, Y. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.10.089 · Cited by 80
Ochsenbein, A. F., Karrer, U., Klenerman, P., Althage, A., Ciurea, A., Shen, H., Miller, J. F., Whitton, J. L., Hengartner, H., & Zinkernagel, R. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9293 · Cited by 65
Nanoparticle vaccines against respiratory viruses
Adair, B. M. (2009) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.45 · Cited by 44
Powell, T., Palath, N., DeRome, M., Tang, J., Jacobs, A., & Boyd, J. G. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.10.001 · Cited by 43
Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres
Kirby, D. J., Rosenkrands, I., Agger, E. M., Andersen, P. L., Coombes, A. G. A., & Perrie, Y. (2008) · Journal of drug targeting · doi:10.1080/10611860802228558 · Cited by 30
PEG-PBLG Nanoparticle-Mediated HSV-TK /GCV Gene Therapy for Oral Squamous Cell Carcinoma
Yu, D., Wang, A., Huang, H., & Chen, Y. (2008) · Nanomedicine · doi:10.2217/17435889.3.6.813 · Cited by 27
Richards, R. L., Rao, M., VanCott, T. C., Matyas, G. R., Birx, D. L., & Alving, C. R. (2004) · Immunology and Cell Biology · doi:10.1111/j.0818-9641.2004.01282.x · Cited by 19
Cited by
Zhao, L., Seth, A., Wibowo, N., Zhao, C.-X., Mitter, N., Yu, C., & Middelberg, A. P. J. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.11.069 · Cited by 919
Synthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 763
Elmowafy, E. M., Tiboni, M., & Soliman, M. E. (2019) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-019-00439-x · Cited by 621
Vaccine delivery using nanoparticles
Gregory, A. E., Titball, R., & Williamson, D. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00013 · Cited by 561
Nanoparticle Vaccines Against Infectious Diseases
Pati, R., Shevtsov, M., & Sonawane, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02224 · Cited by 514
Metadata
- Authors
- Demento, S. L., Cui, W., Criscione, J. M., Stern, E., Tulipan, J., Kaech, S. M., & Fahmy, T. M.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 33
- Issue
- 19
- Pages
- 4957-4964
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2042791775
- Cited by
- 304
- References
- 45
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.